Treatments of patients with GLP-1R agonists promote weight loss and increase circulating adiponectin levels.18 However, little is so far known about GLP-1 treatment effects on human AT in vivo controlled for weight change, apart from a recent study in which Exenatide was started in type-2 diabetic subjects prior to bariatric surgery. The gene discussed is GLP1R; the disease is ataxia telangiectasia.